Q3-osavuosiraportti
31 päivää sitten‧46 min
Tarjoustasot
Oslo Børs
Määrä
Osto
2 002
Myynti
Määrä
90
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 55 | - | - | ||
| 25 | - | - | ||
| 174 | - | - | ||
| 74 | - | - |
Ylin
63,4VWAP
Alin
62,1VaihtoMäärä
4,2 66 183
VWAP
Ylin
63,4Alin
62,1VaihtoMäärä
4,2 66 183
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 29.10. | |
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 5.5. | |
| 2024 Q4-osavuosiraportti | 19.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenExcerpt from Tekinvestor Investor Day 27 Nov 2025 Summary: Status of APL-1702 and the process in CDE "APL-1702 NDA advances to the second round of technical review." "The review pause is a normal part of the process." "The pause does not require the submission of new supplementary documents." "The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process." "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform." Political framework in China "To advance the Healthy China 2030 initiative… the Chinese government has issued key policies, including the Healthy China Initiative: Implementation Plan for Cancer Prevention and Control and the Action Plan for Accelerating Elimination of Cervical Cancer (2023–2030)." "The National Health Commission revealed that the risk of cervical cancer is rising in China, particularly among younger women." "There is still much to be done in the fight to control and prevent this disease." Clinical and social significance of APL-1702 "APL-1702 is a groundbreaking product that combines innovative, clinical, and social value." "It is poised to become the world’s first non-invasive therapy for HSIL." "Clinically, APL-1702 is set to redefine the treatment paradigm of precancerous cervical lesions, moving beyond the one-size-fits-all approach of cervical resection." "It aims to reverse disease progression while preserving the cervix, avoiding damage from resection, and supporting long-term management and recurrence prevention." "APL-1702 combines the value of early cervical cancer intervention and the promotion of a fertility-friendly society." "APL-1702… backed by proven efficacy in an international phase III trial… is expected to contribute to the success of the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030) and the Healthy China Initiative." Platform and portfolio strategy "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform, in a bid to build a comprehensive, tiered gynecological portfolio." "This strategy will center on product iteration and indication expansion, while leveraging synergies across the pipeline to drive broader growth." APL-1706 (Hexvix) / Richard Wolf "Asieris supports Richard Wolf in its efforts to obtain marketing approval for SYSTEM BLUE in China." "SYSTEM BLUE is in the marketing review/approval stage." "APL-1706 continues to be part of the company’s focus areas."
·1 päivä sittenAPL-1702 still appears to be well on its way towards approval in China, and no new requirements or problems are emerging in the process. At the same time, the need for better treatments for cervical cancer in China is enormous, so both APL-1702 and Hexvix have great potential in that market.
·3 päivää sittenPut on the diving goggles again? Paused in the queue again
·3 päivää sittenIn the only remaining one for «pharmacy»? In that case, it's something you can probably take with absolute calm.
·2 päivää sittenOh? There are probably plenty of examples earlier on the list, which gives a good indication that this review can also become time-consuming 😅
·25.11. · MuokattuAsieris with yet another good day on the Shanghai Stock Exchange. Up 5,10% today - that bodes well! Is this when we get a bit of a FOMO-run in Photocure's share price? I certainly don't dare to stay out now, even though it's still unclear how long it will be until there's a clarification regarding Cevira in China. I interpret the rise in Asieris' share price as the issue that was resolved yesterday being an important step forward in the right direction 🤩
·3 päivää sittenDoes it then rise 100% or what do you think ... rakirebsem- ·24.11.Clinical pulled from the queue!
·24.11.The most difficult hurdle has been cleared, and it should no longer be possible to trade PHO at prices near what has been seen in modern times.... It is at least clear which strategy is smartest regarding positioning before or after data/info. Perhaps one even gets the opportunity to buy cheap PHO shares after the approval message is released in China, as Dahl probably needs 15-20 min extra to release the message while Dan is still sleeping.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
31 päivää sitten‧46 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenExcerpt from Tekinvestor Investor Day 27 Nov 2025 Summary: Status of APL-1702 and the process in CDE "APL-1702 NDA advances to the second round of technical review." "The review pause is a normal part of the process." "The pause does not require the submission of new supplementary documents." "The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process." "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform." Political framework in China "To advance the Healthy China 2030 initiative… the Chinese government has issued key policies, including the Healthy China Initiative: Implementation Plan for Cancer Prevention and Control and the Action Plan for Accelerating Elimination of Cervical Cancer (2023–2030)." "The National Health Commission revealed that the risk of cervical cancer is rising in China, particularly among younger women." "There is still much to be done in the fight to control and prevent this disease." Clinical and social significance of APL-1702 "APL-1702 is a groundbreaking product that combines innovative, clinical, and social value." "It is poised to become the world’s first non-invasive therapy for HSIL." "Clinically, APL-1702 is set to redefine the treatment paradigm of precancerous cervical lesions, moving beyond the one-size-fits-all approach of cervical resection." "It aims to reverse disease progression while preserving the cervix, avoiding damage from resection, and supporting long-term management and recurrence prevention." "APL-1702 combines the value of early cervical cancer intervention and the promotion of a fertility-friendly society." "APL-1702… backed by proven efficacy in an international phase III trial… is expected to contribute to the success of the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030) and the Healthy China Initiative." Platform and portfolio strategy "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform, in a bid to build a comprehensive, tiered gynecological portfolio." "This strategy will center on product iteration and indication expansion, while leveraging synergies across the pipeline to drive broader growth." APL-1706 (Hexvix) / Richard Wolf "Asieris supports Richard Wolf in its efforts to obtain marketing approval for SYSTEM BLUE in China." "SYSTEM BLUE is in the marketing review/approval stage." "APL-1706 continues to be part of the company’s focus areas."·1 päivä sittenAPL-1702 still appears to be well on its way towards approval in China, and no new requirements or problems are emerging in the process. At the same time, the need for better treatments for cervical cancer in China is enormous, so both APL-1702 and Hexvix have great potential in that market.
- ·3 päivää sittenPut on the diving goggles again? Paused in the queue again·3 päivää sittenIn the only remaining one for «pharmacy»? In that case, it's something you can probably take with absolute calm.·2 päivää sittenOh? There are probably plenty of examples earlier on the list, which gives a good indication that this review can also become time-consuming 😅
- ·25.11. · MuokattuAsieris with yet another good day on the Shanghai Stock Exchange. Up 5,10% today - that bodes well! Is this when we get a bit of a FOMO-run in Photocure's share price? I certainly don't dare to stay out now, even though it's still unclear how long it will be until there's a clarification regarding Cevira in China. I interpret the rise in Asieris' share price as the issue that was resolved yesterday being an important step forward in the right direction 🤩·3 päivää sittenDoes it then rise 100% or what do you think ... rakirebsem
- ·24.11.Clinical pulled from the queue!·24.11.The most difficult hurdle has been cleared, and it should no longer be possible to trade PHO at prices near what has been seen in modern times.... It is at least clear which strategy is smartest regarding positioning before or after data/info. Perhaps one even gets the opportunity to buy cheap PHO shares after the approval message is released in China, as Dahl probably needs 15-20 min extra to release the message while Dan is still sleeping.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
2 002
Myynti
Määrä
90
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 55 | - | - | ||
| 25 | - | - | ||
| 174 | - | - | ||
| 74 | - | - |
Ylin
63,4VWAP
Alin
62,1VaihtoMäärä
4,2 66 183
VWAP
Ylin
63,4Alin
62,1VaihtoMäärä
4,2 66 183
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 29.10. | |
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 5.5. | |
| 2024 Q4-osavuosiraportti | 19.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
31 päivää sitten‧46 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 29.10. | |
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 5.5. | |
| 2024 Q4-osavuosiraportti | 19.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenExcerpt from Tekinvestor Investor Day 27 Nov 2025 Summary: Status of APL-1702 and the process in CDE "APL-1702 NDA advances to the second round of technical review." "The review pause is a normal part of the process." "The pause does not require the submission of new supplementary documents." "The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process." "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform." Political framework in China "To advance the Healthy China 2030 initiative… the Chinese government has issued key policies, including the Healthy China Initiative: Implementation Plan for Cancer Prevention and Control and the Action Plan for Accelerating Elimination of Cervical Cancer (2023–2030)." "The National Health Commission revealed that the risk of cervical cancer is rising in China, particularly among younger women." "There is still much to be done in the fight to control and prevent this disease." Clinical and social significance of APL-1702 "APL-1702 is a groundbreaking product that combines innovative, clinical, and social value." "It is poised to become the world’s first non-invasive therapy for HSIL." "Clinically, APL-1702 is set to redefine the treatment paradigm of precancerous cervical lesions, moving beyond the one-size-fits-all approach of cervical resection." "It aims to reverse disease progression while preserving the cervix, avoiding damage from resection, and supporting long-term management and recurrence prevention." "APL-1702 combines the value of early cervical cancer intervention and the promotion of a fertility-friendly society." "APL-1702… backed by proven efficacy in an international phase III trial… is expected to contribute to the success of the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030) and the Healthy China Initiative." Platform and portfolio strategy "The company will continue to prioritize APL-1702 and its photodynamic drug-device combination platform, in a bid to build a comprehensive, tiered gynecological portfolio." "This strategy will center on product iteration and indication expansion, while leveraging synergies across the pipeline to drive broader growth." APL-1706 (Hexvix) / Richard Wolf "Asieris supports Richard Wolf in its efforts to obtain marketing approval for SYSTEM BLUE in China." "SYSTEM BLUE is in the marketing review/approval stage." "APL-1706 continues to be part of the company’s focus areas."·1 päivä sittenAPL-1702 still appears to be well on its way towards approval in China, and no new requirements or problems are emerging in the process. At the same time, the need for better treatments for cervical cancer in China is enormous, so both APL-1702 and Hexvix have great potential in that market.
- ·3 päivää sittenPut on the diving goggles again? Paused in the queue again·3 päivää sittenIn the only remaining one for «pharmacy»? In that case, it's something you can probably take with absolute calm.·2 päivää sittenOh? There are probably plenty of examples earlier on the list, which gives a good indication that this review can also become time-consuming 😅
- ·25.11. · MuokattuAsieris with yet another good day on the Shanghai Stock Exchange. Up 5,10% today - that bodes well! Is this when we get a bit of a FOMO-run in Photocure's share price? I certainly don't dare to stay out now, even though it's still unclear how long it will be until there's a clarification regarding Cevira in China. I interpret the rise in Asieris' share price as the issue that was resolved yesterday being an important step forward in the right direction 🤩·3 päivää sittenDoes it then rise 100% or what do you think ... rakirebsem
- ·24.11.Clinical pulled from the queue!·24.11.The most difficult hurdle has been cleared, and it should no longer be possible to trade PHO at prices near what has been seen in modern times.... It is at least clear which strategy is smartest regarding positioning before or after data/info. Perhaps one even gets the opportunity to buy cheap PHO shares after the approval message is released in China, as Dahl probably needs 15-20 min extra to release the message while Dan is still sleeping.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
2 002
Myynti
Määrä
90
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 55 | - | - | ||
| 25 | - | - | ||
| 174 | - | - | ||
| 74 | - | - |
Ylin
63,4VWAP
Alin
62,1VaihtoMäärä
4,2 66 183
VWAP
Ylin
63,4Alin
62,1VaihtoMäärä
4,2 66 183
Välittäjätilasto
Dataa ei löytynyt